Solid Biosciences Long Term Debt

Solid Biosciences (SLDB) currently reports a long-term debt of $18M as of June 2026. That compares with $40M in the prior-year period — down 55.5% year over year. Use the charts on this page to explore Solid Biosciences's long-term debt history and peer comparisons.

Solid Biosciences's long-term debt decreased from $40M to $18M — a 55.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Solid Biosciences reported $18M in long-term debt as of June 2026. That compares with $40M in the prior-year period — down 55.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $18M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Solid Biosciences, and consider following SLDB for alerts when major investors trade the stock.

Solid Biosciences is classified in the Healthcare sector. On long-term debt, it currently shows $18M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SLDB with unrelated industries.